胰腺癌放化疗的研究进展
Advances in Radiotherapy and Chemotherapy for Pancreatic Cancer
DOI: 10.12677/acm.2024.1472030, PDF,   
作者: 韩 冰, 孙晓东*：延安大学医学院，陕西 延安
关键词: 胰腺癌；化疗；放疗；Pancreatic Cancer； Chemotherapy； Radiotherapy
摘要: 胰腺癌位于腹上区和左季肋区的深部，横行于第1、2腰椎平面，紧贴腹后壁，位置较深。在临床实践中，胰腺癌往往发现时已是晚期，严重影响了患者的生活质量。尽管近几年肿瘤学治疗取得了很大进展，但胰腺癌的预后仍相对较差，多年来生存率仅略有改善。胰腺癌的可用治疗方案包括手术、化疗、放疗或靶向治疗等，具体取决于临床分期和患者体能状况。胰腺癌的治疗在全世界仍然是一个挑战，需要多学科的方法来制定最佳治疗方案。本文结合近年来发表的相关文献，对胰腺癌的放化疗现状和进展进行综述。
Abstract: The pancreatic cancer is located in the depth of the superior abdominal region and the left quarterrib region, running across the 1st and 2nd lumbar vertebrae and close to the posterior abdominal wall. In clinical practice, pancreatic cancer is often detected at an advanced stage, which seriously affects the patient’s quality of life. Despite great advances in oncology treatment in recent years, the prognosis for pancreatic cancer remains relatively poor, with survival rates improving only slightly over the years. Available treatment options for pancreatic cancer include surgery, chemotherapy, radiotherapy or targeted therapy, depending on the clinical stage and the patient’s physical condition. The treatment of pancreatic cancer remains a challenge worldwide and requires a multidisciplinary approach to develop the best treatment options. This article reviews the current status and progress of radiotherapy and chemotherapy for pancreatic cancer based on the relevant literature published in recent years.
文章引用：韩冰, 孙晓东. 胰腺癌放化疗的研究进展[J]. 临床医学进展, 2024, 14(7): 414-421. https://doi.org/10.12677/acm.2024.1472030

参考文献

[1] Klein, A.P. (2021) Pancreatic Cancer Epidemiology: Understanding the Role of Lifestyle and Inherited Risk Factors. Nature Reviews Gastroenterology & Hepatology, 18, 493-502. [Google Scholar] [CrossRef] [PubMed]
[2] Diaconescu, S., Gîlcă-Blanariu, G.E., Poamaneagra, S., Marginean, O., Paduraru, G. and Stefanescu, G. (2021) Could the Burden of Pancreatic Cancer Originate in Childhood? World Journal of Gastroenterology, 27, 5322-5340. [Google Scholar] [CrossRef] [PubMed]
[3] 孙德, 曹敏, 李晖, 等. 中国癌症负担及趋势——与日韩的回顾与比较[J]. 中华癌症研究, 2020, 32(2): 129-139.
[4] 魏伟, 曾华, 郑瑞, 等. 中国癌症登记及其在癌症防控中的作用[J]. 柳叶刀肿瘤学, 2020, 21(7): 342-349.
[5] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[6] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Y., Yan, Q., Fan, C., Mo, Y., Wang, Y., Li, X., et al. (2023) Overview and Countermeasures of Cancer Burden in China. Science China Life Sciences, 66, 2515-2526. [Google Scholar] [CrossRef] [PubMed]
[8] Ju, W., Zheng, R., Zhang, S., Zeng, H., Sun, K., Wang, S., et al. (2022) Cancer Statistics in Chinese Older People, 2022: Current Burden, Time Trends, and Comparisons with the US, Japan, and the Republic of Korea. Science China Life Sciences, 66, 1079-1091. [Google Scholar] [CrossRef] [PubMed]
[9] Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., et al. (2020) Preoperative Chemoradiotherapy versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 38, 1763-1773. [Google Scholar] [CrossRef] [PubMed]
[10] Högerle, C., Englhard, A., Simon, F., Grüninger, I., Mlynski, R., Hempel, J., et al. (2021) Cochlear Implant Electrode Tip Fold-Over: Our Experience with Long and Flexible Electrode. Otology & Neurotology, 43, 64-71. [Google Scholar] [CrossRef] [PubMed]
[11] Okusaka, T. and Furuse, J. (2020) Recent Advances in Chemotherapy for Pancreatic Cancer: Evidence from Japan and Recommendations in Guidelines. Journal of Gastroenterology, 55, 369-382. [Google Scholar] [CrossRef] [PubMed]
[12] Walpole, I., Lee, B., Shapiro, J., Thomson, B., Lipton, L., Ananda, S., et al. (2022) Use and Outcomes from Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Ductal Adenocarcinoma in an Australasian Population. Asia-Pacific Journal of Clinical Oncology, 19, 214-225. [Google Scholar] [CrossRef] [PubMed]
[13] 孟庆才, 王巍. 胰腺癌新辅助化疗策略选择及手术时机[J]. 肝胆外科杂志, 2022, 30(1): 73-75.
[14] Flick, K.F., Al-Temimi, M.H., Maatman, T.K., Sublette, C.M., Swensson, J.K., Nakeeb, A., et al. (2020) Hepatic Steatosis after Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes after Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 24, 2008-2014. [Google Scholar] [CrossRef] [PubMed]
[15] Schneider, M., Hackert, T., Strobel, O. and Büchler, M.W. (2021) Technical Advances in Surgery for Pancreatic Cancer. British Journal of Surgery, 108, 777-785. [Google Scholar] [CrossRef] [PubMed]
[16] Biagi, J.J., Cosby, R., Bahl, M., Elfiki, T., Goodwin, R., Hallet, J., et al. (2023) Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline. Current Oncology, 30, 6575-6586. [Google Scholar] [CrossRef] [PubMed]
[17] Conroy, T., Lambert, A. and Ducreux, M. (2023) Adjuvant and Neoadjuvant Approaches in Pancreatic Cancer. Current Opinion in Oncology, 35, 326-333. [Google Scholar] [CrossRef] [PubMed]
[18] Tomimaru, Y., Eguchi, H., Shimomura, Y., Kitamura, T., Inoue, Y., Nagakawa, Y., et al. (2023) Standard versus Delayed Initiation of S-1 Adjuvant Chemotherapy after Surgery for Pancreatic Cancer: A Secondary Analysis of a Nationwide Cohort by the Japan Pancreas Society. Journal of Gastroenterology, 58, 790-799. [Google Scholar] [CrossRef] [PubMed]
[19] Motoi, F. and Unno, M. (2020) Adjuvant and Neoadjuvant Treatment for Pancreatic Adenocarcinoma. Japanese Journal of Clinical Oncology, 50, 483-489. [Google Scholar] [CrossRef] [PubMed]
[20] 何晓文, 张蕾, 卢帅伟, 李开妍. 胰腺癌根治术后应用吉西他滨联合白蛋白紫杉醇辅助化疗的临床观察[J]. 河南医学高等专科学校学报, 2024, 36(1): 23-27.
[21] 王昭月, 杨明, 周军. 2023年度胰腺癌系统治疗研究进展[J]. 肿瘤综合治疗电子杂志, 2024, 10(2): 20-27.
[22] Ren, J., Wu, S., Su, T., Ding, J., Chen, F., Li, J., et al. (2024) Analysis of Chemoresistance Characteristics and Prognostic Relevance of Postoperative Gemcitabine Adjuvant Chemotherapy in Pancreatic Cancer. Cancer Medicine, 13, e7229. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, J., Hua, Q., Wang, H., Zhang, D., Zhao, L., Yu, D., et al. (2021) Meta-analysis and Indirect Treatment Comparison of Modified FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy in Advanced Pancreatic Cancer. BMC Cancer, 21, Article No. 853. [Google Scholar] [CrossRef] [PubMed]
[24] Yeh, C. and Bates, S.E. (2021) Two Decades of Research toward the Treatment of Locally Advanced and Metastatic Pancreatic Cancer: Remarkable Effort and Limited Gain. Seminars in Oncology, 48, 34-46. [Google Scholar] [CrossRef] [PubMed]
[25] 容谦, 周燕华, 洪瑞松, 梁仲惠. FOLFIRINOX方案与吉西他滨方案治疗局限性晚期胰腺癌疗效的对比研究[J]. 现代肿瘤医学, 2021, 29(20): 3605-3609.
[26] Ettrich, T.J. and Seufferlein, T. (2021) Systemic Therapy for Metastatic Pancreatic Cancer. Current Treatment Options in Oncology, 22, Article No. 106. [Google Scholar] [CrossRef] [PubMed]
[27] 侯晶晶. 观察替吉奥(S-1)单药治疗既往未接受过化疗的老年转移性胰腺癌患者的疗效[J]. 临床研究, 2020, 28(1): 17-18.
[28] Salamekh, S., Gottumukkala, S., Park, C., Lin, M. and Sanford, N.N. (2022) Radiotherapy for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 36, 995-1009. [Google Scholar] [CrossRef] [PubMed]
[29] de la Pinta, C. (2024) Stereotactic Body Radiotherapy in Pancreatic Adenocarcinoma. Hepatobiliary & Pancreatic Diseases International, 23, 14-19. [Google Scholar] [CrossRef] [PubMed]
[30] Ermongkonchai, T., Khor, R., Muralidharan, V., Tebbutt, N., Lim, K., Kutaiba, N., et al. (2022) Stereotactic Radiotherapy and the Potential Role of Magnetic Resonance-Guided Adaptive Techniques for Pancreatic Cancer. World Journal of Gastroenterology, 28, 745-754. [Google Scholar] [CrossRef] [PubMed]
[31] Han, D., Gao, F., Liu, J.L., Wang, H., Fu, Q. and Yang, G.W. (2021) Analysis of Radiotherapy Impact on Survival in Resected Stage I/II Pancreatic Cancer Patients: A Population-Based Study. BMC Cancer, 21, Article No. 560. [Google Scholar] [CrossRef] [PubMed]
[32] Ueda, N., Miura, S., Nishiki, H., Hashimoto, A., Kin, R., Fujii, Y., Kaida, D., Tomita, Y., Nakamura, N., Miyata, T., Miyashita, T., Fujita, H. and Takamura, H. (2021) [Significance of Preoperative Chemoradiotherapy for Resectable Pancreatic Cancer]. Gan To Kagaku Ryoho, 48, 1712-1714.
[33] Jin, L., Shi, N., Ruan, S., Hou, B., Zou, Y., Zou, X., et al. (2020) The Role of Intraoperative Radiation Therapy in Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Radiation Oncology, 15, Article No. 76. [Google Scholar] [CrossRef] [PubMed]
[34] Yasuta, S., Kobayashi, T., Aizawa, H., Takahashi, S., Ikeda, M., Konishi, M., et al. (2020) Relationship between Surgical R0 Resectability and Findings of Peripancreatic Vascular Invasion on CT Imaging after Neoadjuvant S-1 and Concurrent Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer. BMC Cancer, 20, Article No. 1184. [Google Scholar] [CrossRef] [PubMed]
[35] Shaib, W.L., Zakka, K., Shahin, A.A., Yared, F., Switchenko, J.M., Wu, C., et al. (2020) Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas, 49, 822-829. [Google Scholar] [CrossRef] [PubMed]
[36] Shibuki, T., Sasaki, M., Yamaguchi, S., Inoue, K., Taira, T., Satake, T., et al. (2023) Palliative Radiotherapy for Tumor Bleeding in Patients with Unresectable Pancreatic Cancer: A Single-Center Retrospective Study. Radiation Oncology, 18, Article No. 178. [Google Scholar] [CrossRef] [PubMed]
[37] Mattiucci, G.C., Boldrini, L., Nardangeli, A., D’Aviero, A., Buwenge, M., Cellini, F., et al. (2020) Hypofractionated Sequential Radiotherapy Boost: A Promising Strategy in Inoperable Locally Advanced Pancreatic Cancer Patients. Journal of Cancer Research and Clinical Oncology, 147, 661-667. [Google Scholar] [CrossRef] [PubMed]
[38] Pasqualetti, F., Sainato, A., Morganti, R., Laliscia, C., Vasile, E., Gonnelli, A., et al. (2021) Adjuvant Radiotherapy in Patients with Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-Analysis and Review of the Literature. Anticancer Research, 41, 4697-4704. [Google Scholar] [CrossRef] [PubMed]

为你推荐